anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,101,710. Phenthiazines. RHONE-POULENC S.A. 20 Oct., 1966 [22 Oct., 1965; 25 Aug., 1966], No. 47046/66. Heading C2C. Compounds of the formula and their acid addition and quaternary ammonium salts, where R is H or CH 3 , R 1  is H, CH 3  or C 2 H 5 , A is a straight or branched C 2-5 - alkylene chain, Y is H or halogen or a C 1-4 - alkyl or -alkoxy group and Z is NH 2 , NH- alkyl or N(alkyl) 2  where the alkyl group contains 1-4 C, are prepared either by transesterification of a compound where R 2  is a C 1-4  alkyl group, with an aminoalcohol of the formula the amino group in Z being protected when necessary and the protecting group being subsequently removed, or by reacting a compound of the formula where X is a halogen atom, with an aminoalcohol with the amino group Z being optionally protected and liberated subsequently. Pharmaceutical compositions having antiinflammatory, anti-rheumatic and spasmolytic activity comprise the compounds of the invention and an inert carrier. The compositions may be in a form suitable for enteral, parenteral or topical administration.
Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
Human papillomaviruses (HPVs) are the most common sexually transmitted infection in the United States and are a major etiological agent of cancers in the anogenital tract and oral cavity. Growing evidence suggests changes in the host microbiome are associated with the natural history and ultimate outcome of HPV infection. We sought to define changes in the host cervicovaginal microbiome during papillomavirus infection, persistence, and pathogenesis using the murine papillomavirus (MmuPV1) cervicovaginal infection model. Cervicovaginal lavages were performed over a time course of MmuPV1 infection in immunocompetent female FVB/N mice and extracted DNA was analyzed by qPCR to track MmuPV1 viral copy number. 16S ribosomal RNA (rRNA) gene sequencing was used to determine the composition and diversity of microbial communities throughout this time course. We also sought to determine whether specific microbial communities exist across the spectrum of MmuPV1-induced neoplastic disease. We, therefore, performed laser-capture microdissection to isolate regions of disease representing all stages of neoplastic disease progression (normal, low- and high-grade dysplasia, and cancer) from female reproductive tract tissue sections from MmuPV1-infected mice and performed 16S rRNA sequencing. Consistent with other studies, we found that the natural murine cervicovaginal microbiome is highly variable across different experiments. Despite these differences in initial microbiome composition between experiments, we observed that MmuPV1 persistence, viral load, and severity of disease influenced the composition of the cervicovaginal microbiome. These studies demonstrate that papillomavirus infection can alter the cervicovaginal microbiome.IMPORTANCEHuman papillomaviruses (HPVs) are the most common sexually transmitted infection in the United States. A subset of HPVs that infect the anogenital tract (cervix, vagina, anus) and oral cavity cause at least 5% of cancers worldwide. Recent evidence indicates that the community of microbial organisms present in the human cervix and vagina, known as the cervicovaginal microbiome, plays a role in HPV-induced cervical cancer. However, the mechanisms underlying this interplay are not well-defined. In this study, we infected the female reproductive tract of mice with a murine papillomavirus (MmuPV1) and found that key aspects of papillomavirus infection and disease influence the host cervicovaginal microbiome. This is the first study to define changes in the host microbiome associated with MmuPV1 infection in a preclinical animal model of HPV-induced cervical cancer. These results pave the way for using MmuPV1 infection models to further investigate the interactions between papillomaviruses and the host microbiome.
OBJECTIVE: Body mass index (BMI) trajectories are associated with night-time sleep, but it is not clear how they relate to daytime sleepiness in population data. This study aimed to examine longitudinal associations between levels and changes in daytime sleepiness and BMI trajectories among men and women.
METHODS: We estimated growth curve models among 827 participants in the Wisconsin Sleep Cohort Study (mean [sd] age = 55.2 [8.0] years at baseline). The outcome variable was BMI (kg/m2) and the key predictor was daytime sleepiness measured by Multiple Sleep Latency Test (MSLT) scores. Covariates included demographics, health behaviors, retirement status, stimulant use, and depressive symptoms. In sensitivity analyses, we evaluated the potential effects of cardiovascular disease, shift work status, and sleep apnea on the robustness of sleepiness and BMI associations.
RESULTS: At the between-person level, men who were sleepier had higher BMI levels. At the within-person level, age moderated the positive association between sleepiness and BMI among women. Specifically, young women who became sleepier over time gained more BMI than older women with comparable increases in sleepiness. Furthermore, while BMI tended to increase with age among women, BMI trajectories were steeper among sleepy women than among well-rested women, who experienced less increase in BMI over time.
CONCLUSION: The study suggested that levels and changes in daytime sleepiness as objectively measured by MSLT scores are associated with body mass among adults.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder characterized by the progressive fibro-fatty replacement of the right ventricular myocardium, leading to myocardial atrophy. Although the structural changes usually affect the right ventricle, the pathology may also manifest with either isolated left ventricular myocardium or biventricular involvement. As ARVC shows an autosomal dominant pattern of inheritance with variable penetrance, the clinical presentation of the disease is highly heterogeneous, with different degrees of severity and patterns of myocardial involvement even in patients of the same familiar group with the same gene mutation: the pathology spectrum ranges from the absence of symptoms to sudden cardiac death (SCD) sustained by ventricular arrhythmias, which may, in some cases, be the first manifestation of an otherwise silent pathology. An evidence-based systematic review of the literature was conducted to evaluate the state of the art of the diagnostic techniques for the correct post-mortem identification of ARVC. The research was performed using the electronic databases PubMed and Scopus. A methodological approach to reach a correct post-mortem diagnosis of ARVC was described, analyzing the main post-mortem peculiar macroscopic, microscopic and radiological alterations. In addition, the importance of performing post-mortem genetic tests has been underlined, which may lead to the correct identification and characterization of the disease, especially in those ARVC forms where anatomopathological investigation does not show evident morphostructural damage. Furthermore, the usefulness of genetic testing is not exclusively limited to the correct diagnosis of the pathology, but is essential for promoting targeted screening programs to the deceased's family members. Nowadays, the post-mortem diagnosis of ARVC performed by forensic pathologist remains very challenging: therefore, the identification of a clear methodological approach may lead to both a reduction in under-diagnoses and to the improvement of knowledge on the disease.
PURPOSE:To inexpensively produce tea having good taste and provided in effective action of aloe by finely cutting fresh leaf of aloe, blending the cut aloe leaf with tea leaf and treating the mixture in same production process of tea. CONSTITUTION:A fresh leaf 1 of aloe is diagonally cut while paying attention not so as to enlarge surface area of gel-like leaf flesh in epidermis 4 to afford aloe pieces 2 and 3. The resultant aloe pieces 2 and 3 are added to tea leaf in rough tea production process. The addition amount of aloe pieces is about 200g based on 1kg tea leaf. These ingredients are sufficiently stirred and blended. Then the blend is steamed by 100 deg.C steam and after returning to ordinary temperature, the blend is subjected to crude rolling for about 30min while applying 100 deg.C air in air amount of 0.8 to 1.2m<2>/min based on 1kg weight of aloe pieces and removing water content. The blend is rolled by applying 100 deg.C hot air in air amount of 50% in the air rolling for about 15-20min and finely twisted and then dried to complete production process of rough tea.
Participants enrolled in nutrition education comparison group will receive 6 educational lessons related to promoting early childhood healthy growth. Lessons will be delivered bi-weekly for no longer than 4-months total. The lessons are from the evidence-based Family Spirit Nurture curriculum.
Background: The role of severity and duration of inflammatory findings on the development of persistent hypothyroidism and anemia has not been clarified in subacute thyroiditis (SAT). Methods: Demographic data and laboratory parameters of patients with SAT were analyzed retrospectively. Results: Permanent hypothyroidism was observed in 28.1% of patients. Baseline elevated erythrocyte sedimentation rate as defined >74.5 mm/h was found to be associated with permanent hypothyroidism, but the duration of inflammation was not different between the recovered and hypothyroid patients. Baseline hemoglobin values improved without specific therapy in 3.5 months. Conclusion: The initial severity but not the duration of inflammation increases the risk for the development of permanent thyroid dysfunction, and anemia improves with the resolution of inflammation.
PURPOSE:The titled aqueous solution improving clouding, useful for improving peripheral circulation, etc., obtained by adding a nonionic surface active agent to a solution having a specific pH, wherein an alpha-tocopherol phosphoric ester is dissolved as a pharmaceutically acceptable water-soluble salt. CONSTITUTION:A stable aqueous solution of alpha-tocopherol phosphoric ester, wherein an alpha-tocopherol phosphoric ester is dissolved as a pharmaceutically acceptable water-soluble salt (e.g., alkali metal salt), having 3-9pH, preferably 5-8pH, containing a nonionic surface active agent. The nonionic surface active agent has preferably 11-20HLB. The amount of it used is >=15(W/W), preferably >=100(W/W) based on alpha-tocopherol phosphoric ester. Defects such as clouding, etc. with respect to pharmaceutical manufacturing, obstacles in the preparation of an aqueous solution of hydrophilic alpha-tocopherol, caused by the adjustment of concentration or pH, can be improved.
Disclosed embodiments describe techniques for motion analysis based on human body mounted sensors. The motion analysis enables diagnosis and treatment using mapping and motion analysis. The wearable sensors include inertial measurement sensors, muscle activation sensors, stretch sensors, or linear displacement sensors. Data is obtained from two or more sensors attached to a body part of an individual, where the two or more sensors enable collection of motion data of the body part, and where the two or more sensors include at least one inertial measurement unit (IMU) and at least one sensor determining muscle activation. The locations of each of the two or more sensors are mapped into a coordinate reference system, based on the data. Motion of the human body is calculated based on the mapping. A movement signature is determined based on the calculated motion. The movement signature is used to analyze a movement disorder of the individual.
No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
PURPOSE: To obtain a medicinal compsn. having activity to viral infection due to human immunodeficiency. CONSTITUTION: This medicinal compsn. contains a bonded cyclic compd. represented by the formula Z-(A)n -Y, its acid addition salt and metallic complex as active components and a medicinally allowable diluent, carrier or excipient. In the formula, each of Z and Y is a 9- to 32-membered polyheterocyclic component having 3-8 nuclear hetero atoms in the rings, especially 1,4,8,11- tetrazacyclotetradecane, 1,5,9,13-tetrazacyclohexadecane or 1,5,8,11,14- pentazacyclohexadecane, the hetero atoms are selected from among N, O and S, A is a bonded atom or group, especially alkanediyl and (n) is 0 or an integer of 1-6.
Bicuspid aortic valve (BAV), the most common congenital heart defect, is a major cause of aortic valve disease requiring valve interventions and thoracic aortic aneurysms predisposing to acute aortic dissections. The spectrum of BAV ranges from early onset valve and aortic complications (EBAV) to sporadic late onset disease. Rare genomic copy number variants (CNVs) have previously been implicated in the development of BAV and thoracic aortic aneurysms. We determined the frequency and gene content of rare CNVs in EBAV probands (n = 272) using genome-wide SNP microarray analysis and three complementary CNV detection algorithms (cnvPartition, PennCNV, and QuantiSNP). Unselected control genotypes from the Database of Genotypes and Phenotypes were analyzed using identical methods. We filtered the data to select large genic CNVs that were detected by multiple algorithms. Findings were replicated in a BAV cohort with late onset sporadic disease (n = 5040). We identified 3 large and rare (< 1,1000 in controls) CNVs in EBAV probands. The burden of CNVs intersecting with genes known to cause BAV when mutated was increased in case-control analysis. CNVs intersecting with GATA4 and DSCAM were enriched in cases, recurrent in other datasets, and segregated with disease in families. In total, we identified potentially pathogenic CNVs in 9% of EBAV cases, implicating alterations of candidate genes at these loci in the pathogenesis of BAV.
PURPOSE:To obtain a detergent compsn. which has a high detergency, hardly irritates or injures the skin, can be washed away easily and is excellent in feeling during use by compounding high-molecular particles having a specified particle size, particle size distribution, and specific gravity into the compsn. CONSTITUTION:The detergent compsn. contains high-molecular particles having a mean particle size of 50-500mum, a coefficient of variation of particle size of 25% or lower, and a specific gravity of 1 or lower. A mean particle size lower than 50mum gives an insufficient detergency; one higher than 500mum causes a sense of incongruity and skin irritation. A coefficient of variation higher than 25% requires a large amt. of particles to be compounded to obtain a sufficient detergency, resulting in problems such as skin irritation, a sense of incongruity, and coming into an eye. A specific gravity higher than 1 makes the removal of the particles from the skin or eye during washing difficult and sometimes causes a sense of incongruity. The particles pref. have a modulus of elasticity of 1X10<3>-5X10<5>dyn/cm<2> in terms of irritation and injury to the skin.
The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+/−0.5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kDa may be optimally used, and is selected from a group including: dextran, polyethylene glycol and albumin. As regards insulin formulations used, it is possible to use human recombinant insulin and genetically engineered analogs thereof used in the commercial formulations. Experiments have shown that using the aforementioned polymers provides insulin formulations with a prolonged effect without the use of chemical or genetic methods of modifying insulin molecules. The method of long acting formulations preparing is not dependent on biotherapeutics and thus it can be used over range of therapeutic proteins.
Compositions and methods for manufacturing polymers are disclosed. Compositions include novel plastics, including films and shaped forms comprising polymer matrices that are biologically compatible and biodegradable. Such plastics may comprise polymers derived from natural sources. Further, such plastics are useful in biological systems for wound repair, implants, stents, drug encapsulation and delivery, and other applications. The disclosed methods comprise mild manufacturing processes such that various additives, such as biologically active proteins, sugars, lipids, and the like may be incorporated into the polymer matrix without subsequent loss of bioactivity during processing. Additionally, methods of manufacture for controlling mechanical properties, such as elasticity, pliancy, and the porosity of such plastics are disclosed.
OBJECTIVE: To determine the barriers and enablers oral health and chronic disease policymakers identify during policy development.
METHODS: Semi-structured interview questions were developed utilizing an interview guide and applying a knowledge mobilization framework. Reflective thematic analysis of the data was completed based on the research of Braun and Clarke encompassing a critical realist approach.
RESULTS: Twelve policymakers were interviewed. Policymakers reported barriers to accessing evidence including the sheer volume of information and a lack of: research summaries, comprehensive oral health data sets, open access articles, consistency of reporting, and time. They did find relationships with experts and intermediaries crucial at times to policy development. Co-creation of research was also a key enabler for policymakers.
CONCLUSIONS: This study highlights that policymakers find evidence crucial during the development of policy and often use it to advocate for policies. However, the links between poor oral health; and cardiovascular disease, diabetes, and cognitive impairment are not well recognized among chronic disease policymakers. It is important that oral health researchers and policymakers work to close this gap. The treatment of poor oral health is a global population health issue. It is imperative that evidence of these links is implemented into health policy for the treatment and prevention of chronic diseases and improved quality of life for individuals living with chronic diseases.
During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
This invention provides a new family of dietary supplements containing polyunsaturated fatty acids, a probiotic culture, and optionally hydrolyzed collagen. The prototype supplement contains cranberry seed oil as a source of omega-3 and omega-6 fatty acids, along with Vitamin E. The prototype supplement also contains a special strain of Lactobacillus casei as well as fish collagen. Nutritional supplements of this invention can be provided in capsule or tablet form, or as a food item such as a chocolate confectionary. Each of the three ingredients confers benefits on their own, allowing the consumer to get three nutritional supplements in the convenience of a single product. The ingredients are also believed to work synergistically to achieve a wider and more durable overall effect. In human clinical trials, consumption of the dietary supplement was associated subjective observations of improvement in softness and moisture of facial skin, reduction in wrinkles, and improvement in function of the gastrointestinal tract.
Thrombocytopenia has been reported with NINLARO with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle [see Adverse Reactions (6.1)]. Grade 3 thrombocytopenia was reported in 17% of patients in the NINLARO regimen and Grade 4 thrombocytopenia was reported in 13% in the NINLARO regimen. The rate of platelet transfusions was 10% in the NINLARO regimen and 7% in the placebo regimen.

Monitor platelet counts at least monthly during treatment with NINLARO. Consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications [see Dosage and Administration (2.2)] and platelet transfusions as per standard medical guidelines.
The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering 2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-exadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide (Compound I), or a pharmaceutically acceptable salt thereof, and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. The other anti-HCV agent can be a HCV polymerase inhibitor, an HCV NS5A inhibitor, an HCV entry inhibitor, a cyclophilin inhibitor, or an internal ribosome entry site inhibitor. Preferably, the other anti-HCV agent is an HCV polymerase inhibitor. Also preferably, the other anti-HCV agent is an HCV NS5A inhibitor. Also preferably, the other anti-HCV agent is administered concurrently with Compound I or a pharmaceutically acceptable salt thereof. In another example, the other anti-HCV agent is administered sequentially with Compound I or a pharmaceutically acceptable salt thereof. In still another embodiment, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with two or more other anti-HCV agents. For instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with an HCV polymerase inhibitor and an HCV NS5A inhibitor. For another instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with two different HCV polymerase inhibitors (e.g., one is a nucleoside polymerase inhibitor and the other is a non-nucleoside polymerase inhibitor; or both are nucleoside polymerase inhibitors; or both are non-nucleoside polymerase inhibitor). In yet another example, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with another HCV protease inhibitor and an HCV polymerase inhibitor. In still another example, Compound I (or a pharmaceutically acceptable salt thereof) is administered with two different HCV NS5A inhibitors.
The invention discloses a kind of recombinant protein resisting PRV (Pseudorabies virus) propagation, this recombinant protein synthesis for resist PRV (Pseudorabies virus) medicine in apply.The recombinant protein of opposing PRV (Pseudorabies virus) propagation, does is its aminoacid sequence by SEQ? ID? the protein of the aminoacid sequence composition shown in No.2; Or with sequence SEQ? ID? the amino acid sequence homology that No.2 limits at the aminoacid sequence of 95 ~ 100% coding identical function protein, or; SEQ? ID? aminoacid sequence shown in No.2 through increasing, lack or replace one or more amino acid and there is the derivative albumen of same isoreactivity.Recombinant protein is used for resisting in the medicine of PRV (Pseudorabies virus) by the present invention, and experiment proves: have significant inhibition.